Cryo Cell International (CCEL) Q4 2025 earnings summary

Executive summary

• Fiscal 2025 consolidated revenues were $31.6 million, slightly down from $32.0 million in fiscal 2024.

• Net loss of $2.4 million for fiscal 2025, compared to net income of $402,000 in fiscal 2024.

• Impairment charge of $4.4 million recognized in Q4 2025 to reduce public inventory to net realizable value.

Financial highlights

• Processing and storage fee revenue was $31.4 million in 2025, compared to $31.6 million in 2024.

• Product revenue was $54,000 in 2025, down from $68,000 in 2024.

• Public banking revenue was $130,000 in 2025, down from $367,000 in 2024.

• Basic and diluted loss per share was $0.30 in 2025, compared to earnings of $0.05 per share in 2024.

Risk factors and uncertainties

• Risks include success of global expansion, product diversification, and IP portfolio.

• Uncertainties around future profitability from biopharmaceutical manufacturing and clinics.

• Potential impact from public cord blood banking competition and collaborative research outcomes.

• Complexities and timing related to potential Celle Corp. spinoff.